AMENDMENTS TO THE CLAIMS

Please cancel claims 1-12 and 14

Please amend claim 13 as follows:

13. (Amended) A method [of] for treating a human to alleviate or prevent the pathological effects of hyperparathyroidism secondary to end stage renal disease, [wherein the method comprises] comprising administering in a non-oral dosage form to [the] a human in need thereof a vitamin D analog selected from the group consisting of 1α–OH-vitamin D_2, 1α–OH-vitamin D_4, and 1α,24(R)–$(OH)_2$-vitamin D_4, wherein [said] the analog is administered to the human in an amount sufficient to lower elevated or maintain lowered serum parathyroid hormone levels in the human to thereby alleviate or prevent the pathological effects.

Please add the following claims:

15. (New) The method of claim 13 wherein the analog is administered in combination with at least one agent characterized by the agent's ability to reduce loss of bone mass, or bone mineral content in the human.

16. (New) The method of claim 15 wherein the agent is selected from the group consisting of other vitamin D compounds, conjugated estrogens, sodium fluorides, biphosphonates, cobalamin, pertussin toxin or boron.

17. (New) The method of claim 13 wherein the analog is administered in a dosage amount of from about 1 μg to about 100 μg per week.

18. (New) The method of claim 13 wherein said analog is administered parenterally in a dosage amount of about 1 μg to 30 μg given 1 to 3 times per week.

19. (New) The method of claim 13, wherein the analog is co-administered with a calcium-based phosphate binder.

20. (New) The method of claim 13, wherein the analog is 1α-OH-vitamin D_2.